365mc, Korea’s leading clinic specializing in liposuction, said it has signed a strategic partnership with Israel-based global biopharmaceutical company Raziel Therapeutics to jointly develop a next-generation fat reduction solution.

The agreement was signed on July 11 at the headquarters of OC Health Wellness Group in Orange County, California.

The two companies will combine 365mc’s LAMS (Local Anesthesia Minimal Invasive Liposuction) procedure, a minimally invasive fat extraction technique under local anesthesia, with Raziel’s novel fat-dissolving injection, RZL-012, to create a combined body contouring solution.

The collaboration aims not only to introduce RZL-012 to the Korean market but also to accelerate its global expansion into China, the Middle East, and the U.S.

RZL-012, currently entering phase 3 trials with the U.S. FDA, is an injectable drug designed to selectively destroy fat cell membranes, reducing localized subcutaneous fat without surgery.

Clinical results have shown up to 34 percent fat layer reduction with a single treatment in areas such as the double chin, abdomen, thighs, and flanks.

In China, Raziel is conducting phase 3 trials through a licensing deal worth approximately 100 billion won ($72 million) with Fosun Pharma. The combination of RZL-012 with GLP-1 receptor agonist, such as Wegovy, offers the potential for simultaneous weight loss and targeted body contouring, making it an attractive option for combined obesity and aesthetic management.

Developed in Korea in 2014, 365mc’s LAMS procedure enables effective fat removal without skin incisions, delivering immediate visible results. By combining LAMS’s rapid fat extraction with RZL-012’s sustained fat cell destruction, the two companies aim to introduce a novel body contouring paradigm.

The companies plan to officially brand the integrated treatment as the 365mc-Raziel Combined Therapy Model and jointly present it at major international aesthetic medicine conferences, including IMCAS and AMWC.

365mc will serve as a key partner for the introduction and expansion of RZL-012 in Korea.

Operating 28 clinics worldwide, 365mc offers integrated obesity management, including liposuction, dietary counseling, and behavioral modification. Drawing on its extensive clinical experience and regulatory expertise, the company plans to take part in generating domestic clinical data and expediting local drug approval.

“This integrated treatment solution will combine the advanced technologies and expertise of both companies, delivering differentiated, customer-centered body contouring treatments,” 365mc CEO Kim Nam-chul said. “We expect it to set a new standard of innovation and become a leading model in the global aesthetic medicine market.”

Raziel Therapeutics CEO Alon Bloomenfeld also said, “365mc’s robust clinical experience and global network will play a pivotal role in accelerating the clinical expansion and commercialization of RZL-012.”

With the body contouring market growing at an annual rate of over 8 percent, this partnership will be a key driver of growth and market presence for both companies, Bloomenfeld added.